Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma

被引：1
|
作者：
Lipschitz, Noga [1 ]
Earl, Brian R. [1 ,2 ]
Cripe, Timothy P. [3 ,4 ]
Samy, Ravi N. [1 ,5 ,6 ]
机构：
[1] Univ Cincinnati, Coll Med, Dept Otolaryngol Head & Neck Surg, Cincinnati, OH USA
[2] Univ Cincinnati, Dept Commun Sci & Disorders, Coll Allied Hlth Sci, Cincinnati, OH USA
[3] Nationwide Childrens Hosp, Dept Pediat, Div Hematol Oncol Blood & Marrow Transplant, Columbus, OH USA
[4] Nationwide Childrens Hosp, Ctr Childhood Canc & Blood Dis, Res Inst, Columbus, OH USA
[5] Univ Cincinnati, Neurosensory Disorders Ctr, Gardner Neurosci Inst, 213 Albert Sabin Way,MSB 6407, Cincinnati, OH 45267 USA
[6] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
来源：
CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY | 2020年 / 28卷 / 05期
关键词：
cholesteatoma; herpes simplex virus; oncolytic virotherapy; TALIMOGENE LAHERPAREPVEC; ACQUIRED CHOLESTEATOMA; VIRUS; SAFETY; ADENOVIRUS; MELANOMA; EFFICACY; PATHOGENESIS; COMBINATION; HSV-1;
D O I：
10.1097/MOO.0000000000000651
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Purpose of review To review the principles of oncolytic virotherapy and summarize the recent preliminary evidence on the efficacy of oncolytic virotherapy for cholesteatoma (CHST) treatmentin vitroin human CHST cells and in a gerbil CHST model. Recent findings The use of oncolytic virotherapy for nonmalignant lesions is innovative. In-vitro results showed that oncolytic herpes simplex virus 1 (oHSV) selectively targets and kills CHST cells. In a gerbil model of CHST, local oHSV injections were associated with a decrease in CHST volume and modulation of bony changes. Surgical treatment options for CHST are limited by high morbidity and recidivism, emphasizing the need for developing treatment alternatives. Preliminary results support the potential therapeutic effect of oncolytic virotherapy on CHST, yet further research is needed to evaluate this novel approach.
引用
收藏
页码：281 / 285
页数：5
相关论文
共 50 条
  • [21] What is oncolytic virotherapy?
    Cockle, Julia V.
    Scott, Karen J.
    ARCHIVES OF DISEASE IN CHILDHOOD-EDUCATION AND PRACTICE EDITION, 2018, 103 (01): : 43 - 45
  • [22] Cytokines in oncolytic virotherapy
    Pol, Jonathan G.
    Workenhe, Samuel T.
    Konda, Prathyusha
    Gujar, Shashi
    Kroemer, Guido
    CYTOKINE & GROWTH FACTOR REVIEWS, 2020, 56 : 4 - 27
  • [23] Oncolytic Virotherapy by HSV
    Watanabe, Daisuke
    Goshima, Fumi
    HUMAN HERPESVIRUSES, 2018, 1045 : 63 - 84
  • [24] Advances in oncolytic virotherapy
    Stephen J. Russell
    John C. Bell
    Christine E. Engeland
    Grant McFadden
    Communications Medicine, 2
  • [25] Personalizing oncolytic virotherapy?
    Kaur, Balveen
    Chiocca, E. Antonio
    MOLECULAR THERAPY, 2007, 15 (01) : 6 - 7
  • [26] Poxvirus oncolytic virotherapy
    Torres-Dominguez, Lino E.
    McFadden, Grant
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (06) : 561 - 573
  • [27] Harnessing the Potential of Combination Immunotherapy and Oncolytic Virotherapy for Solid Tumors
    Sonia Cohen
    Genevieve M. Boland
    Annals of Surgical Oncology, 2022, 29 : 762 - 763
  • [28] Neurotropic Influenza A Virus as a Potential Oncolytic Virotherapy for Glioblastoma and Melanoma
    Klonoski, Josh
    Snook, Jeremy
    Palmer, Cheryl
    VanBrocklin, Matthew
    Williams, Matthew
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2020, 79 (06): : 673 - 673
  • [29] Harnessing the Potential of Combination Immunotherapy and Oncolytic Virotherapy for Solid Tumors
    Cohen, Sonia
    Boland, Genevieve M.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (02) : 762 - 763
  • [30] Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy
    Sampath, Padma
    Thorne, Steve H.
    ONCOLYTIC VIROTHERAPY, 2015, 4 : 75 - 82
12345